Blood tests for diagnosing dementia are a step closer for UK
Category: Alzheimer’s Disease
Biogen drops Alzheimer’s drug Aduhelm
31 January 2024; Biogen has announced that it will discontinue the development and commercialisation of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study. This decision is not related to any safety or efficacy concerns. A large portion of the resources released resulting from termination of the ADUHELM programme will…
New twice weekly Alzheimer’s disease patch
Alzheimer’s disease treatment can help reduce symptoms and lessen the care burden for patients and their caregivers September 2023: Zeyzelf® twice weekly rivastigmine transdermal patch is for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia and it is the first ever patch to be launched in the UK that does not need daily…
Can the scent of essential oils improve memory?
From Medscape, August 8th 2023. Inhaling a pleasant aroma during sleep has been linked to an improvement in memory, small-scale early research suggests. Researchers randomly assigned 43 older adults, aged 60 – 85 years, to receive either nightly exposure to essential oil scents delivered via a diffuser (n = 20; mean [SD] age, 70.1 [6.6]…
FDA approves LEQEMBI™ (lecanemab-irmb)
Traditional approval for the treatment of Alzheimer’s disease in the US July 6, 2023: Eisai Co Ltd and Biogen Inc have announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous use, making LEQEMBI the first and…
THN391 – First in-human dosing in phase 1 trial in Alzheimer’s disease
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease THN391 binds to the inflammation-driving component of fibrin that is known to activate pathological immune responses in neurodegenerative and ophthalmologic diseases. Based on preclinical studies to date, targeting this region does not impact or diminish fibrin’s critical…
Why is Alzheimer’s Gene APOE4 less dangerous for people of African descent?
Researchers at the John P Hussman Institute for Human Genomics at the University of Miami Miller School of Medicine, US have found that variations in chromatin accessibility, and thus gene expression, may explain why people of European descent with APOE4 gene variants have a greater risk of developing Alzheimer’s disease than people of African descent with similar…
Gamma-Frequency Sensory Stimulation decreases brain atrophy in patients with Alzheimer’s disease
On March 30th 2023 Cognito Therapeutics announced neuroimaging results evaluating the effects of the company’s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in participants with Alzheimer’s disease (AD). The results were presented at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, on March…
Lecanemab: Clarity AD clinical study results
Results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical study of lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were presented at the…
